Literature DB >> 1808223

Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations.

C Eisenberg1, N Seta, M Appel, G Feldmann, G Durand, J Feger.   

Abstract

We have characterized a binding site for galactosyl terminal glycoproteins in hepatocytes isolated from human biopsies. The binding of asialoorosomucoid on hepatocytes previously treated by Triton X-100 was saturable, calcium-dependent and highly affine (Ka = 1.11 +/- 0.87.10(9) M-1) thus corresponding to a ligand-receptor binding. The total number of receptors in the normal human liver was 140,000 +/- 65,000 sites per cell. This corresponded to the value obtained in the human hepatoma cell line HepG2, but was significantly lower than for isolated rat hepatocytes. Furthermore, in hepatocytes isolated from livers with histological features of either fibrosis, cirrhosis, hepatocarcinoma with cirrhosis or nodular regenerative hyperplasia, the number of asialoglycoprotein receptors per cell was increased, while the binding affinity was unchanged.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808223     DOI: 10.1016/0168-8278(91)90073-k

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Feasibility on systemic delivery of asialoorosomucoid complex to hepatic origin cells mediated by asialoglycoprotein receptor.

Authors:  Sun Jun; Jinsong Xia; Yu Wang; Yuzhe Wang; Zong Yiqiang; Qu Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

2.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

3.  Porphyrin and galactosyl conjugated micelles for targeting photodynamic therapy.

Authors:  De-Qun Wu; Ze-Yong Li; Cao Li; Jian-Jun Fan; Bo Lu; Cong Chang; Si-Xue Cheng; Xian-Zheng Zhang; Ren-Xi Zhuo
Journal:  Pharm Res       Date:  2009-11-04       Impact factor: 4.200

4.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

5.  Neisseria gonorrhoeae utilizes and enhances the biosynthesis of the asialoglycoprotein receptor expressed on the surface of the hepatic HepG2 cell line.

Authors:  N Porat; M A Apicella; M S Blake
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

Review 6.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.

Authors:  Katherine L Gill; Krishna K Machavaram; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

Review 7.  Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.

Authors:  Yueran Yu; Shangda Li; Weifeng Liang
Journal:  Emerg Microbes Infect       Date:  2018-07-26       Impact factor: 7.163

8.  Nanoparticle-Mediated Dual Targeting: An Approach for Enhanced Baicalin Delivery to the Liver.

Authors:  Iman Saad Ahmed; Hassan Medhat Rashed; Hend Fayez; Faten Farouk; Rehab Nabil Shamma
Journal:  Pharmaceutics       Date:  2020-01-29       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.